Fluorometholone

Identification

Summary

Fluorometholone is an ophthalmic corticosteroid used for the relief of inflammation located in both the palpebral and bulbar conjunctiva, the cornea, and the anterior segment of the globe of the eye.

Brand Names

FML, FML Forte Liquifilm, FML-S, Flarex, Fluor-OP

Generic Name

Fluorometholone

DrugBank Accession Number

DB00324

Background

A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)

Type

Small Molecule

Groups

Approved, Investigational

Structure

Similar Structures

Weight: Average: 376.4617
Monoisotopic: 376.204987621
Chemical Formula: C₂₂H₂₉FO₄

Synonyms

(1R,2S,8S,10S,11S,14R,15S,17S)-14-acetyl-1-fluoro-14,17-dihydroxy-2,8,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one
9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
Fluorometholon
Fluorométholone
Fluorometholone
Fluorometholonum
Fluorometolona

External IDs

NSC 33001
U 17323

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

For the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Dose Form
Used in combination to treat	Anterior chamber inflammation	Combination Product in combination with: Tetryzoline (DB06764)	••••••••••••	••••••••• •••••••• • •••••
Adjunct therapy in treatment of	Bacterial eye infection		••• •••••
Used in combination to treat	Conjunctivitis allergic	Combination Product in combination with: Tetryzoline (DB06764)	••••••••••••	••••••••• •••••••• • •••••
Used in combination to treat	Corneal inflammation	Combination Product in combination with: Tetryzoline (DB06764)	••••••••••••	••••••••• •••••••• • •••••
Treatment of	Eye inflammation		••••••••••••

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Corticosteroids such as fluorometholone inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.

Mechanism of action

There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Their primary target is the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes.

Target	Actions	Organism
AGlucocorticoid receptor	agonist	Humans

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Side effects may include acute anterior uveitis and perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. LD₅₀ = 234 mg/kg (rats)

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Abametapir	The serum concentration of Fluorometholone can be increased when it is combined with Abametapir.
Abatacept	The risk or severity of adverse effects can be increased when Fluorometholone is combined with Abatacept.
Acarbose	The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Acarbose.
Aceclofenac	The risk or severity of gastrointestinal irritation can be increased when Fluorometholone is combined with Aceclofenac.
Acemetacin	The risk or severity of gastrointestinal irritation can be increased when Fluorometholone is combined with Acemetacin.

Food Interactions

No interactions found.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Fluorometholone acetate	9I50C3I3OK	3801-06-7	YRFXGQHBPBMFHW-SBTZIJSASA-N

International/Other Brands

Efflumidex (Allergan) / Fluaton (Allergan) / Flumetholon (Ferron) / Flurolon (Allergan) / FML Liquifilm (Allergan) / Foxone (Winston) / Fucin (Mey See) / Fuluson (Dae Wo) / Fumelon (Han Lim) / Humetoron (Kuk Je) / Oxylone

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Flarex	Suspension	0.1 % w/v	Ophthalmic	Novartis	1987-12-31	Not applicable
Flarex	Suspension / drops	1 mg/1mL	Ophthalmic	ALCON LABORATORIES, INC.	1992-02-06	Not applicable
Flarex	Suspension / drops	1 mg/1mL	Ophthalmic	Eyevance Pharmaceuticals	2019-03-05	Not applicable
Fluor-Op	Suspension	0.1 mL/100mL	Ophthalmic	Novartis Ophthalmics	2006-05-11	Not applicable
FML	Suspension / drops	1 mg/1mL	Ophthalmic	Allergan, Inc.	1972-02-01	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Fluorometholone	Solution / drops	1 mg/1mL	Ophthalmic	REMEDYREPACK INC.	2019-03-01	2020-06-01
Fluorometholone	Solution / drops	1 mg/1mL	Ophthalmic	Pacific Pharma, Inc.	1997-10-31	Not applicable
Fluorometholone Ophthalmic Suspension	Suspension / drops	1 mg/1mL	Ophthalmic	Amneal Pharmaceuticals NY LLC	2023-01-09	Not applicable
Fluorometholone Ophthalmic Suspension	Suspension / drops	1 mg/1mL	Ophthalmic	Amneal Pharmaceuticals NY LLC	2023-01-09	Not applicable
PMS-fluorometholone	Suspension	0.1 %	Ophthalmic	Pharmascience Inc	2001-07-16	2016-10-28

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
EFEMOLINE 5 ML DAMLA	Fluorometholone (1 mg/ml) + Tetrahydrozoline hydrochloride (0.25 mg/ml)	Solution / drops	Ophthalmic	THEA PHARMA İLAÇ TİC.LTD. ŞTİ.	2011-11-18	Not applicable
FLU-SURE T® SUSPENSIÓN OFTÁLMICA	Fluorometholone (1 mg) + Tetrahydrozoline hydrochloride (0.25 mg)	Suspension	Ophthalmic	ARBOFARMA S.A.S.	2012-10-03	Not applicable
FML-neo Oph Sus	Fluorometholone (0.1 %) + Neomycin sulfate (0.5 %)	Suspension	Ophthalmic	Allergan	1977-12-31	2011-08-04
FML-S	Fluorometholone (1.0 mg/1mL) + Sulfacetamide sodium (100 mg/1mL)	Suspension	Ophthalmic	Allergan	2007-02-20	Not applicable
Tobraflex	Fluorometholone acetate (1 mg/1mL) + Tobramycin (3 mg/1mL)	Suspension	Ophthalmic	Alcon, Inc.	1989-07-21	1989-07-21

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
FLUOROPOS GOZ DAMLASI 1MG/ML 5ML	Fluorometholone (1 mg/ml)	Solution / drops	Ophthalmic	BİEM İLAÇ SAN. VE TİC. A.Ş.	2020-08-14	2020-12-09

Chemical Identifiers

UNII: SV0CSG527L
CAS number: 426-13-1
InChI Key: FAOZLTXFLGPHNG-KNAQIMQKSA-N
InChI: InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1
IUPAC Name: (1R,3aS,3bS,5S,9aS,9bR,10S,11aS)-1-acetyl-9b-fluoro-1,10-dihydroxy-5,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one
SMILES: [H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C

References

Synthesis Reference

Fried, J.; U.S. Patent 2,852,51 September 16,1958; assigned to Olin Mathieson Chemical Corporation.  Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; US. Patent 2,867,637; January 6, 1959; assigned to The Upjohn Company . Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; U.S. Patent 2,867,638; January 6, 1959; assigned to The Upjohn Company.  Magerlein, B.J., Kagan, F. and Schlagel, C.A.; U.S. Patent 3,038,914; June 12, 1962; assigned to The Upjohn Company.

General References

FDA Approved Drug Products: FML (fluorometholone) ophthalmic suspension [Link]

External Links

Human Metabolome Database: HMDB0014469
KEGG Drug: D01367
PubChem Compound: 9878
PubChem Substance: 46505984
ChemSpider: 9494
BindingDB: 50103631
RxNav: 4491
ChEBI: 31625
ChEMBL: CHEMBL1200600
ZINC: ZINC000118912517
Therapeutic Targets Database: DAP001047
PharmGKB: PA164781355
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
PDRhealth: PDRhealth Drug Page
Wikipedia: Fluorometholone

FDA label

Download (64.7 KB)

MSDS

Download (72 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Completed	Treatment	Adenoviral Keratoconjunctivitis	1
4	Completed	Treatment	Intraocular Pressure (IOP)	1
4	Not Yet Recruiting	Treatment	Fuchs' Endothelial Dystrophy / Intraocular Pressure (IOP) / Pseudophakic Bullous Keratopathy	1
4	Not Yet Recruiting	Treatment	Steroid Ophthalmic Insert	1
4	Unknown Status	Health Services Research	Dry Eye Syndrome (DES) / Inflammation / Microvessels	1

Pharmacoeconomics

Manufacturers

Pharmacia and upjohn co
Allergan pharmaceutical
Novartis pharmaceuticals corp
Alcon laboratories inc

Packagers

Alcon Laboratories
Allergan Inc.
A-S Medication Solutions LLC
Bausch & Lomb Inc.
Dispensing Solutions
Novartis AG
OMJ Pharmaceuticals
Pacific Pharma Lp
Pharma Pac LLC
Pharmedix
Physicians Total Care Inc.

Dosage Forms

Form	Route	Strength
Suspension	Conjunctival; Ophthalmic	1 mg
Solution / drops	Ophthalmic
Solution / drops	Ophthalmic	0.1 %
Suspension	Ophthalmic	0.1 % w/v
Suspension	Ophthalmic	1 mg
Ointment	Ophthalmic
Ointment	Ophthalmic	0.1 %
Solution / drops	Ophthalmic	0.2 %
Suspension	Conjunctival; Ophthalmic	100000 mg
Suspension	Ophthalmic	1.000 mg
Suspension	Ophthalmic; Topical	1 mg
Suspension	Ophthalmic; Topical	100000 mg
Suspension	Ophthalmic	0.1 mL/100mL
Solution / drops	Ophthalmic	1 mg/1mL
Solution / drops	Ophthalmic	1 mg/ml
Ointment	Ophthalmic	1 mg/1g
Suspension	Ophthalmic	0.1 %
Suspension / drops	Ophthalmic	1 mg/1mL
Suspension / drops	Ophthalmic	2.5 mg/1mL
Suspension	Ophthalmic	0.25 %
Solution	Ophthalmic	1 mg/ml
Suspension / drops	Conjunctival	0.1 % w/v
Suspension	Ophthalmic
Suspension / drops	Ophthalmic	0.1 %
Suspension	Conjunctival; Ophthalmic
Suspension	Conjunctival; Intraocular; Ophthalmic
Solution / drops	Ophthalmic
Suspension / drops	Conjunctival
Liquid	Ophthalmic	1 mg/1ml

Prices

Unit description	Cost	Unit
FML Liquifilm 0.1% Suspension 15ml Bottle	82.16USD	bottle
FML Forte 0.25% Suspension 15ml Bottle	60.98USD	bottle
FML Liquifilm 0.1% Suspension 10ml Bottle	60.17USD	bottle
Flarex 0.1% Suspension 10ml Bottle	50.7USD	bottle
FML Forte 0.25% Suspension 10ml Bottle	48.58USD	bottle
Flarex 0.1% Suspension 5ml Bottle	42.82USD	bottle
FML Liquifilm 0.1% Suspension 5ml Bottle	41.65USD	bottle
FML-S Liquifilm 0.1-10% Suspension 10ml Bottle	35.99USD	bottle
Fluor-Op 0.1% Suspension 15ml Bottle	30.99USD	bottle
FML Forte 0.25% Suspension 5ml Bottle	30.07USD	bottle
Fluor-Op 0.1% Suspension 10ml Bottle	25.99USD	bottle
Fluor-Op 0.1% Suspension 5ml Bottle	17.99USD	bottle
Flarex 0.1% eye drops	8.11USD	ml
Fml liquifilm 0.1% eye drop	6.27USD	ml
Fml forte 0.25% eye drops	5.09USD	ml
Fluorometholone 0.1% drops	3.25USD	ml
Fml Forte 0.25 % Suspension	2.96USD	ml
Flarex 0.1 % Suspension	1.96USD	ml
Pms-Fluorometholone 0.1 % Suspension	1.73USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	292-303	Fried, J.; U.S. Patent 2,852,51 September 16,1958; assigned to Olin Mathieson Chemical Corporation.  Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; US. Patent 2,867,637; January 6, 1959; assigned to The Upjohn Company . Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; U.S. Patent 2,867,638; January 6, 1959; assigned to The Upjohn Company.  Magerlein, B.J., Kagan, F. and Schlagel, C.A.; U.S. Patent 3,038,914; June 12, 1962; assigned to The Upjohn Company.
water solubility	30 mg/L (at 25 °C)	YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP	2.00	HANSCH,C ET AL. (1995)
logS	-4.1	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.0166 mg/mL	ALOGPS
logP	2.34	ALOGPS
logP	2.42	Chemaxon
logS	-4.4	ALOGPS
pKa (Strongest Acidic)	12.65	Chemaxon
pKa (Strongest Basic)	-3.4	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	4	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	74.6 Å²	Chemaxon
Rotatable Bond Count	1	Chemaxon
Refractivity	100.87 m³·mol^-1	Chemaxon
Polarizability	39.94 Å³	Chemaxon
Number of Rings	4	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9956
Blood Brain Barrier	+	0.9716
Caco-2 permeable	+	0.8169
P-glycoprotein substrate	Substrate	0.7834
P-glycoprotein inhibitor I	Non-inhibitor	0.6791
P-glycoprotein inhibitor II	Non-inhibitor	0.8382
Renal organic cation transporter	Non-inhibitor	0.8397
CYP450 2C9 substrate	Non-substrate	0.8762
CYP450 2D6 substrate	Non-substrate	0.907
CYP450 3A4 substrate	Substrate	0.7663
CYP450 1A2 substrate	Non-inhibitor	0.9149
CYP450 2C9 inhibitor	Non-inhibitor	0.8345
CYP450 2D6 inhibitor	Non-inhibitor	0.9232
CYP450 2C19 inhibitor	Non-inhibitor	0.9285
CYP450 3A4 inhibitor	Non-inhibitor	0.8309
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9452
Ames test	Non AMES toxic	0.9025
Carcinogenicity	Non-carcinogens	0.9404
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.3393 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9694
hERG inhibition (predictor II)	Non-inhibitor	0.5956

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	splash10-01qd-2923000000-d51e17b0fa8439e2bc18
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	splash10-0079-2960000000-57c1831d283834b32701
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0079-2960000000-57c1831d283834b32701
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0a4r-0009000000-25b8222bd2f625ea8997
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-004i-0009000000-c8b4ec260ee10a8925df
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0a4l-0679000000-8599023096391eb0b98d
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-00q9-0009000000-746f8fcb6c72dcf07f6f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-01q9-0309000000-1e71037542f90a1ec9fd
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-00dr-0392000000-6017694a59839e4c9217
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å²)	Source type	Source
[M-H]-	193.454293	predicted	DarkChem Lite v0.1.0
[M-H]-	178.7936128	predicted	DarkChem Lite v0.1.0
[M-H]-	190.0317	predicted	DeepCCS 1.0 (2019)
[M+H]+	195.074593	predicted	DarkChem Lite v0.1.0
[M+H]+	186.1119747	predicted	DarkChem Lite v0.1.0
[M+H]+	191.92708	predicted	DeepCCS 1.0 (2019)
[M+Na]+	194.054393	predicted	DarkChem Lite v0.1.0
[M+Na]+	185.2282366	predicted	DarkChem Lite v0.1.0
[M+Na]+	197.5807	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Glucocorticoid receptor

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Agonist

General Function: Zinc ion binding
Specific Function: Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name: NR3C1
Uniprot ID: P04150
Uniprot Name: Glucocorticoid receptor
Molecular Weight: 85658.57 Da

References

Samudre SS, Lattanzio FA Jr, Williams PB, Sheppard JD Jr: Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther. 2004 Dec;20(6):533-47. [Article]
Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [Article]
Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [Article]
Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [Article]
Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [Article]
Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [Article]

Enzymes

Details1. Cytochrome P450 3A5

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inducer

General Function: Oxygen binding
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP3A5
Uniprot ID: P20815
Uniprot Name: Cytochrome P450 3A5
Molecular Weight: 57108.065 Da

References

Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]

Details2. Cytochrome P450 3A4

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate
Inducer

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

El-Sankary W, Bombail V, Gibson GG, Plant N: Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos. 2002 Sep;30(9):1029-34. [Article]
Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]

Carriers

Details1. Corticosteroid-binding globulin

Kind: Protein
Organism: Humans
Pharmacological action: Unknown

General Function: Steroid binding
Specific Function: Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name: SERPINA6
Uniprot ID: P08185
Uniprot Name: Corticosteroid-binding globulin
Molecular Weight: 45140.49 Da

References

Moisan MP, Castanon N: Emerging Role of Corticosteroid-Binding Globulin in Glucocorticoid-Driven Metabolic Disorders. Front Endocrinol (Lausanne). 2016 Dec 19;7:160. doi: 10.3389/fendo.2016.00160. eCollection 2016. [Article]
Gardill BR, Vogl MR, Lin HY, Hammond GL, Muller YA: Corticosteroid-binding globulin: structure-function implications from species differences. PLoS One. 2012;7(12):e52759. doi: 10.1371/journal.pone.0052759. Epub 2012 Dec 26. [Article]

Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55

Fluorometholone

Identification

Structure for Fluorometholone (DB00324)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)

Targets

References

Enzymes

References

References

Carriers

References